Why does postpartum depression matter?
The postpartum period is often portrayed as a time of joy and adjustment. However, for many, it is also marked by significant psychological distress. Postpartum depression is one of the most common complications in the postnatal period, affecting more than one in ten mothers within the first year after birth. Despite its prevalence, it remains both underdiagnosed and undertreated. Alarmingly, suicide accounts for approximately 20% of postpartum deaths.
The consequences of postpartum depression (PPD) extend beyond maternal wellbeing and can profoundly affect the mother–infant relationship. Mothers experiencing PPD may struggle with emotional availability, responsiveness, and confidence in caregiving, which can impair bonding and attachment. These disrupted early interactions occur during a critical period of infant neurodevelopment and may have lasting impacts on the child’s emotional, cognitive, and behavioural development. Evidence suggests that children of mothers with untreated PPD are at increased risk of social and emotional difficulties in later adolescence
In addition to its psychosocial impact, postpartum depression (PPD) has been linked to adverse physical health outcomes in infants. These may include feeding difficulties, poor weight gain, and higher rates of health concerns. Such outcomes are thought to arise from challenges with breastfeeding, reduced engagement with healthcare services, and difficulties in interpreting and responding to infant cues. The cumulative effect of these factors can place significant strain on both families and healthcare systems.
Recognising PPD as a condition with significant short and long-term consequences highlights why it matters clinically. Effective identification and timely management not only improve maternal mental health but also play a crucial role in promoting healthy infant development and supporting overall family wellbeing.
What do we mean by postpartum depression?
Postpartum depression (PPD) is a major depressive episode that can occur anytime within 12 months from birth. While transient mood disturbance may be common after delivery, PPD is characterised by persistent symptoms, functional impairment and significant distress. It is important to be able to distinguish PPD from other postnatal mood conditions:
- Baby Blues: Women may experience symptoms such as tearfulness, mood liability and irritability. These symptoms usually peak around days 3-5 but last no longer than two weeks, which is the key differentiating factor.
- Postpartum anxiety: Women with postpartum depression often present with pervasive feelings of sadness, hopelessness, and emotional pain, frequently centred around their baby’s wellbeing and their perceived ability to care for them. While postpartum anxiety can co-exist with depression, the two are distinct conditions. Postpartum anxiety is typically characterised by excessive fear and worry, whereas postpartum depression is more often associated with low mood, despair, and emotional withdrawal.
- Postpartum psychosis: A rare but severe psychiatric emergency characterised by a rapid onset of psychotic symptoms such as hallucinations, delusions and mania.
Risk factors for postpartum depression
There are numerous recognised risk factors for postpartum depression (PPD), reflecting the complex interplay between psychological, social, and environmental stressors.
Among the strongest predictors are prenatal depression and anxiety. Other key factors include impaired mother–infant interactions, limited social or financial support, and relationship or marital conflict.
Women who go on to develop PPD often experience significantly higher levels of daily stress. In fact, scores on the Everyday Stressor Index (ESI) have been reported to be up to three times higher than those of healthy controls.
This aligns with broader evidence showing that exposure to significant stress – particularly from adverse life events increases the risk of PPD. Such stressors may include bereavement, relationship breakdown, financial insecurity, and a history of trauma, including previous sexual abuse.
Pathophysiology
The pathophysiology of PPD is not yet fully understood, but current evidence suggests a multifactorial process involving hormonal changes, genetic susceptibility and alterations in the immune and neurobiological function.
During pregnancy, there are substantial increases in reproductive hormones, particularly oestrogen and progesterone, with levels peaking in the third trimester. After delivery, the expulsion of the placenta results in a rapid and marked decline in circulating hormone levels, as the placenta was the primary source during pregnancy.
This abrupt hormone withdrawal is thought to play a key role in the development of PPD in susceptible individuals. Oestrogen and progesterone influence a wide range of biological systems, including regulation of the hypothalamic-pituitary-adrenal (HPA) axis, immune and thyroid function, lactogenic hormone regulation and gene expression, all of which have been implicated in mood regulation.
In addition to fluctuations in oestrogen and progesterone, reductions in allopregnanolone—a neuroactive metabolite of progesterone—have been associated with postpartum depression (PPD).
Allopregnanolone acts as a positive allosteric modulator of gamma-aminobutyric acid type A (GABA<sub>A</sub>) receptors, enhancing the inhibitory effects of GABA in the central nervous system. When allopregnanolone levels fall, this GABAergic inhibition is reduced, potentially contributing to affective instability and depressive symptoms.
This proposed mechanism has gained clinical relevance with the development of neurosteroid-based treatments for PPD. These therapies support the hypothesis that altered GABAergic signalling plays a central role in the disorder’s pathophysiology.
Management
The management of postpartum depression (PPD) is multifaceted and should be individualised according to symptom severity, maternal preference and the wider psychosocial context.
Non-pharmacological management
Non-pharmacological interventions are a cornerstone of care, especially for women who are breastfeeding or prefer to avoid medication. These approaches should support both maternal mental health and the integrity of the mother–infant relationship.
Supporting the breastfeeding mother
Breastfeeding difficulties are common in the early postnatal period and may both precede and exacerbate depressive symptoms. Mothers experiencing pain, low confidence or challenges with feeding benefit from early referral to a skilled lactation professional. Feeding difficulties may result in inadequate milk transfer, unsettled infant behaviour and frequent crying, which can be perceived as a “challenging infant temperament”, and significantly increase maternal stress.
Addressing these issues early can boost maternal confidence, reduce distress, and support the development of a more positive feeding relationship.
Importantly, referral for lactation support should be considered even in the absence of overt depressive symptoms. Unresolved breastfeeding difficulties can contribute to the later development—or worsening—of postpartum depression.
In addition to professional input, mother-to-mother support groups and peer counselling programmes can offer shared experience, reassurance, and a valuable sense of social connection.
Psychosocial support and lifestyle measures
For women with mild depressive symptoms, enhanced psychosocial support may be enough.
Additional follow-up visits with obstetric, primary care, or paediatric clinicians offer valuable opportunities for reassurance, validation, and open discussion about the transition to motherhood.
Practical strategies—such as optimising rest, improving nutrition, engaging in gentle physical activity, and practising mindfulness—may help reduce stress and support overall wellbeing.
Helping women to identify and access family, social, and community resources can also alleviate external stressors and reduce feelings of isolation.
Peer support interventions, whether delivered in person or virtually, are highly acceptable to many women and have been shown to reduce depressive symptoms. Nondirective counselling, provided by trained professionals or paraprofessionals, can offer additional support, although its impact is generally more modest than that of structured psychological therapies.
Psychological therapies
When symptoms are moderate or persistent, referrals to formal psychological therapy are recommended. Cognitive behavioural therapy (CBT) and interpersonal psychotherapy (IPT) are the most extensively studied psychological interventions for postpartum depression, and have been specifically adapted for perinatal populations. Both are time-limited, evidence-based treatments with comparable efficacy, and improvements are sustained at longer-term follow-up. Other psychological approaches, including psychodynamic therapies, may also be effective.
Many women express a preference for psychological over pharmacological treatment, particularly during lactation. Concerns about medication exposure through breast milk can otherwise act as a barrier to engagement with care, and these preferences should be explored and respected wherever clinically appropriate.
Multidisciplinary approach
Optimal care for women with postpartum depression is best delivered through a multidisciplinary approach that recognises the interconnectedness of maternal mental health, infant wellbeing, and the mother–infant relationship.
Collaborative models of care highlight the value of shared responsibility, open communication, and coordinated support between healthcare professionals across disciplines.
ntegrated approaches that bring together paediatric, lactation, and mental health expertise demonstrate how coordinated assessment and intervention can simultaneously address feeding difficulties, psychological adjustment, and infant health.
These models emphasise the bidirectional relationship between breastfeeding challenges and postpartum depression, reinforcing the importance of assessing risk factors—even when screening scores appear low.
While formal interdisciplinary clinics may not be universally available, the same principles can be applied in routine practice. Close collaboration between midwives, health visitors, family physicians, paediatric clinicians, lactation consultants, advanced practice nurses, and perinatal mental health specialists is key to delivering effective, holistic care.
When to escalate
Severe postpartum depression, particularly when associated with suicidal ideation, homicidal thoughts, or psychotic features, constitutes a psychiatric emergency and requires urgent mental health assessment. Although not first-line for most women, somatic treatments such as electroconvulsive therapy (ECT) may be considered in cases of severe, treatment-resistant illness.
Emerging evidence also suggests a potential role for focal brain stimulation therapies, such as repetitive transcranial magnetic stimulation, particularly for women who do not respond to psychotherapy or wish to avoid antidepressant medication while breastfeeding. Further research is required to establish their safety and effectiveness in postpartum populations.
Pharmacological management
While non-pharmacological interventions remain central to care, pharmacological treatment plays an important role in managing moderate to severe postpartum depression (PPD), or when symptoms do not respond adequately to psychological therapies alone.
Treatment decisions should carefully weigh the potential risks of medication exposure—particularly during breastfeeding—against the significant risks of untreated maternal depression. These include impaired maternal functioning, disrupted bonding, and adverse outcomes for the infant.
Antidepressant medications
For those with moderate to severe symptoms or inadequate response to therapy alone, a combination of psychological treatment and antidepressant medication is recommended. Referral to specialist perinatal mental health or behavioural health services may be appropriate, particularly when symptoms are complex or severe.
Selective serotonin reuptake inhibitors (SSRIs) are the first-line pharmacological treatment for postpartum depression. Sertraline and escitalopram are commonly recommended as initial options, with sertraline having the most extensive and reassuring safety data—particularly in breastfeeding women.
If SSRIs are ineffective or not well tolerated, alternatives such as serotonin–norepinephrine reuptake inhibitors (SNRIs) or mirtazapine may be considered.
Importantly, women who have previously responded well to a particular antidepressant should generally be supported to continue or resume that medication during pregnancy or the postpartum period, even if it is not considered a first-line agent.
Fluoxetine and paroxetine may be associated with a higher risk of neonatal adaptation syndrome; however, prior individual response remains an important consideration, and switching medications solely for theoretical neonatal risk may increase the likelihood of maternal relapse.
Antidepressants and breastfeeding
When treating lactating women, clinicians should discuss the benefits of breastfeeding, the potential risks of antidepressant exposure via breast milk, and the risks of untreated maternal depression. Most antidepressants are considered compatible with breastfeeding, and serious adverse events in healthy, full-term infants are rare.
Sertraline is generally preferred when initiating treatment, due to its minimal passage into breast milk. However, switching from another effective SSRI solely for lactation safety is not usually recommended.
SNRIs and mirtazapine also appear to have low levels of breast milk transfer. In contrast, bupropion is generally avoided due to rare reports of infant seizures. Among the tricyclic antidepressants, nortriptyline has the most favourable safety profile, while doxepin is contraindicated.
In some cases, breastfeeding difficulties themselves may contribute to ongoing depressive symptoms. When feeding challenges are a major source of distress, formula feeding may be a healthy and appropriate alternative—particularly in settings where safe preparation is assured.
Neurosteroid therapies
Advances in understanding the neurobiology of postpartum depression have led to the development of neurosteroid-based treatments targeting GABAergic dysfunction.
Brexanolone—an intravenous formulation of allopregnanolone and a positive allosteric modulator of GABAA receptors—was approved by the FDA in 2019 for the treatment of moderate to severe postpartum depression.
It is administered as a continuous 60-hour inpatient infusion and has shown rapid and clinically meaningful reductions in depressive symptoms. However, access remains limited due to its high cost, the requirement for inpatient monitoring, and enrolment in a Risk Evaluation and Mitigation Strategy (REMS) programme.
Adverse effects such as sedation, hypoxia, and loss of consciousness have been reported, necessitating close observation throughout the infusion. Breastfeeding is not recommended during treatment or for several days afterwards. In addition, long-term efficacy and safety data remain limited.
Zuranolone, an oral neuroactive steroid and GABAA receptor modulator, received FDA approval in 2023 for the treatment of postpartum depression.
It is taken once daily for 14 days and may be used as monotherapy or alongside traditional antidepressants. Zuranolone has a rapid onset of action, with improvements in symptoms often seen within days.
However, it is associated with central nervous system side effects, particularly somnolence. Patients should be advised about the risk of impairment during activities such as driving or operating machinery.
Due to limited safety data, zuranolone is not recommended during pregnancy or breastfeeding. Additionally, treatment beyond the initial 14-day course is not currently advised.
How might postpartum depression present in practice?
The clinical presentation of postpartum depression is varied and often subtle. While some women describe persistent sadness or tearfulness, others may report emotional numbness, irritability or overwhelming guilt. Fatigue, poor concentration and sleep disturbance are common, but these symptoms are easily attributed to the normal demands of new parenthood.
Less obvious presentations are particularly important to recognise. Women may attend repeatedly with non-specific physical complaints, struggle to engage with healthcare professionals or even express a disproportionate concern regarding their baby’s health.
Statements such as “I should be coping better than this” or “Everyone else seems to manage” may offer mixed cues. The fear of judgment or of being perceived as an inadequate parent often leads women to minimise or conceal their concerns.
Screening and diagnosis
Postpartum depression remains significantly under-recognised, with estimates suggesting that up to half of affected women are never formally identified.
Many women do not perceive their symptoms as pathological, instead attributing feelings of low mood, anxiety, or emotional distress to the expected challenges of new parenthood. Others may be reluctant to disclose symptoms due to fear of stigma, embarrassment, or concerns about being judged as an inadequate parent.
In some cases, women worry that speaking up could lead to unwanted involvement from social services or even separation from their baby.
These barriers underscore the importance of proactive, routine screening—rather than relying solely on self-report—to ensure timely identification and support.
Early identification of postpartum depression is essential to ensure timely access to mental health assessment, treatment, and support.
The Edinburgh Postnatal Depression Scale (EPDS) is one of the most widely used screening tools for postpartum depression. Originally developed in the UK, it is a 10-item self-report questionnaire that takes less than five minutes to complete and reliably identifies women at increased risk of depression.
Importantly, the EPDS is not a diagnostic tool. Instead, it is designed to facilitate open conversations about maternal mental health and help guide decisions about further evaluation.
Screening is often conducted within the first few days after birth. Higher scores—or the presence of additional risk factors—should prompt closer follow-up and a more comprehensive assessment.
While screening tools are most frequently used in the immediate postpartum setting, they are equally valuable throughout the first postnatal year. Mental health professionals, primary care clinicians, obstetric providers, paediatric clinicians and health visitors are all well placed to screen for postpartum depression and should remain vigilant, even when formal screening is not routinely implemented.
Overall, clinical judgement remains essential. Screening results should always be interpreted alongside a broader assessment of symptoms, psychosocial context and known risk factors.
Women with a history of depression or anxiety, limited social support, socioeconomic stressors or significant life events are at increased risk. Infant-related factors, including perceived difficult temperament or ongoing breastfeeding difficulties, may further contribute to maternal stress.
Given the recognised association between lactation challenges and postpartum depression, mothers presenting with feeding difficulties should be considered for mental health screening, even in the absence of overt psychological symptoms.
Take home notes
PPD is common, underdiagnosed and potentially life-threatening, with significant consequences for both mother and infant if untreated.
Risk is highest in women with antenatal depression or anxiety, significant psychosocial stressors, trauma history, poor social support or breastfeeding difficulties.
Symptoms may be subtle and masked by normal postpartum fatigue, requiring proactive enquiry rather than reliance on spontaneous disclosure.
Routine screening, particularly using the EPDS is essential but should always be interpreted alongside clinical judgement and known risk factors.
Early, individualised intervention improves outcomes and should prioritise psychological therapies, social support and preservation of the mother-infant relationship.
SSRIs (particularly sertraline) are first-line pharmacological treatments for moderate to severe PPD and are generally compatible with breastfeeding.
Neurosteroid therapies offer rapid symptom relief in selected severe cases but are limited by access, safety considerations and breastfeeding restrictions.
A multidisciplinary approach integrating obstetric, paediatric, lactation and mental health care, is central to effective prevention, detection and management of PPD.
References
Stewart DE, Vigod SN. Postpartum depression: pathophysiology, treatment, and emerging therapeutics. Annual review of medicine. 2019 Jan 27;70(1):183-96..
NHS UK – Post-natal depression
Cleveland Clinic – Post-partum anxiety
NHS UK – Post-partum psychosis
Stevens LM, Lynm C, Glass RM. Postpartum depression. JAMA. 2010 Oct 20;304(15):1736-.
Andrews-Fike C. A review of postpartum depression. Primary care companion to the Journal of clinical psychiatry. 1999 Feb;1(1):9.
Williamson JA, O’Hara MW, Stuart S, Hart KJ, Watson D. Assessment of postpartum depressive symptoms: the importance of somatic symptoms and irritability. Assessment. 2015 Jun;22(3):309-18.
Postpartum Depression: A Guide for Front-Line Health and Social Service Providers
Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Archives of women’s Mental Health. 2005 Jun;8(2):77-87.
Payne JL, Maguire J. Pathophysiological mechanisms implicated in postpartum depression. Frontiers in neuroendocrinology. 2019 Jan 1;52:165-80.
Webber E, Benedict J. Postpartum depression: A multi-disciplinary approach to screening, management and breastfeeding support. Archives of psychiatric nursing. 2019 Jun 1;33(3):284-9.
Carlson K, Mughal S, Azhar Y, Siddiqui W, May K. Perinatal Depression (Nursing). InStatPearls [Internet] 2025 Jan 22. StatPearls Publishing.
Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N. Zuranolone for the treatment of postpartum depression. American Journal of Psychiatry. 2023 Sep 1;180(9):668-75.
Garafola S, Shiferaw E, Dev V. Safety of brexanolone in adults with postpartum depression: postmarketing surveillance data. Drugs-Real World Outcomes. 2023 Sep;10(3):351-6.
Oliveira TA, Luzetti GG, Rosalém MM, Neto CM. Screening of perinatal depression using the Edinburgh Postpartum Depression Scale. Revista Brasileira de Ginecologia e Obstetrícia/RBGO Gynecology and Obstetrics. 2022 May;44(05):452-7.
